CN111566090A - 罗沙司他及其中间体的制备方法 - Google Patents

罗沙司他及其中间体的制备方法 Download PDF

Info

Publication number
CN111566090A
CN111566090A CN201880076576.2A CN201880076576A CN111566090A CN 111566090 A CN111566090 A CN 111566090A CN 201880076576 A CN201880076576 A CN 201880076576A CN 111566090 A CN111566090 A CN 111566090A
Authority
CN
China
Prior art keywords
formula
compound
acid
reaction mass
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880076576.2A
Other languages
English (en)
Chinese (zh)
Inventor
A·R·莱卡拉
J·达希亚巴伊利拉卡尔
M·阿西夫
R·R·布德戴夫
S·M·纳瑞亚姆
R·班迪乔
S·S·帕邱里
S·R·萨卡尔
B·伊蕾妮
D·马拉
K·K·多尼帕尔蒂
V·K·R·巴达尔拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of CN111566090A publication Critical patent/CN111566090A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880076576.2A 2017-12-01 2018-11-30 罗沙司他及其中间体的制备方法 Pending CN111566090A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201741043126 2017-12-01
IN201741043126 2017-12-01
IN201841019627 2018-05-25
IN201841019627 2018-05-25
PCT/IB2018/059504 WO2019106621A1 (en) 2017-12-01 2018-11-30 Process for the preparation of roxadustat and its intermediates

Publications (1)

Publication Number Publication Date
CN111566090A true CN111566090A (zh) 2020-08-21

Family

ID=66664380

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880076576.2A Pending CN111566090A (zh) 2017-12-01 2018-11-30 罗沙司他及其中间体的制备方法

Country Status (8)

Country Link
US (1) US20200299242A1 (https=)
EP (1) EP3717456A4 (https=)
JP (1) JP2021504440A (https=)
CN (1) CN111566090A (https=)
BR (1) BR112020011040A2 (https=)
CA (1) CA3083672A1 (https=)
RU (1) RU2020121746A (https=)
WO (1) WO2019106621A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115144480A (zh) * 2021-03-31 2022-10-04 成都倍特药业股份有限公司 一种从罗沙司他中间体中检测吗啉和/或四甲基甲烷二胺的方法
CN116903532A (zh) * 2023-06-02 2023-10-20 珠海优润医药科技有限公司 一种罗沙司他的制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2709493C1 (ru) * 2019-08-01 2019-12-18 Марат Феликсович Фазылов Способ получения роксадустата
US20220340532A1 (en) 2019-08-07 2022-10-27 Teva Pharmaceuticals International Gmbh Processes for the preparation of roxadustat and intermediates thereof
CN113248432B (zh) * 2021-04-25 2022-12-13 南京正济医药研究有限公司 高收率制备罗沙司他中间体的新方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104024227A (zh) * 2011-07-22 2014-09-03 北京贝美拓新药研发有限公司 抑制脯氨酸羟化酶活性的化合物的晶型及其应用
CN104892509A (zh) * 2015-06-04 2015-09-09 苏州明锐医药科技有限公司 诺得司他的制备方法
CN106478504A (zh) * 2016-09-29 2017-03-08 上海勋和医药科技有限公司 制备Roxadustat中间体的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2528232C (en) * 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
EP2872487B1 (en) * 2012-07-16 2017-04-26 Fibrogen, Inc. Process for making isoquinoline compounds
CN108383787A (zh) * 2017-11-05 2018-08-10 王兆举 诺得司他的制备方法
CN108424388B (zh) * 2018-04-19 2020-08-21 杭州科巢生物科技有限公司 一种慢性贫血药物的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104024227A (zh) * 2011-07-22 2014-09-03 北京贝美拓新药研发有限公司 抑制脯氨酸羟化酶活性的化合物的晶型及其应用
CN104892509A (zh) * 2015-06-04 2015-09-09 苏州明锐医药科技有限公司 诺得司他的制备方法
CN106478504A (zh) * 2016-09-29 2017-03-08 上海勋和医药科技有限公司 制备Roxadustat中间体的方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115144480A (zh) * 2021-03-31 2022-10-04 成都倍特药业股份有限公司 一种从罗沙司他中间体中检测吗啉和/或四甲基甲烷二胺的方法
CN115144480B (zh) * 2021-03-31 2023-11-28 成都倍特药业股份有限公司 一种从罗沙司他中间体中检测吗啉和/或四甲基甲烷二胺的方法
CN116903532A (zh) * 2023-06-02 2023-10-20 珠海优润医药科技有限公司 一种罗沙司他的制备方法

Also Published As

Publication number Publication date
JP2021504440A (ja) 2021-02-15
WO2019106621A1 (en) 2019-06-06
CA3083672A1 (en) 2019-06-06
EP3717456A4 (en) 2021-09-15
EP3717456A1 (en) 2020-10-07
US20200299242A1 (en) 2020-09-24
BR112020011040A2 (pt) 2020-11-17
RU2020121746A (ru) 2022-01-04

Similar Documents

Publication Publication Date Title
CN111566090A (zh) 罗沙司他及其中间体的制备方法
US11465970B2 (en) Method for synthesis of Roxadustat and intermediate compounds thereof
JPS5858354B2 (ja) セフェム誘導体
JPH0730018B2 (ja) 新規化合物の３−アミノ−２−オキソアゼチジン誘導体及びそれらの製造法
CN107531677A (zh) 用于制备托匹司他及其中间体的方法
CN111491941A (zh) 新型烷基二苯甲烷保护剂
US20050227914A1 (en) New process
TWI689495B (zh) 用於製備３-羥基吡啶甲酸的方法
JPH0751591B2 (ja) 新規複素環置換酢酸誘導体
WO2016078505A1 (zh) 芴乙酮衍生物的制备方法
BR112020004825B1 (pt) Processo aperfeiçoado para a preparação de trifloxistrobina
JP4022070B2 (ja) 新規チアゾール化合物およびその製造方法
JPS597717B2 (ja) セフアロスポリン誘導体およびその製造法
CS196371B2 (en) Method of preparing 2-lower alkyl-7-substituted 2-or 3-cephem-4-carboxylic acids
JPH0791304B2 (ja) セフェムプロドラッグエステルの新規製造法
JP2006500409A (ja) Ｎｏ供与ジクロフェナクのようなｎｏ供与化合物の製造方法
WO1998057923A1 (en) New production process
CN101160288B (zh) 烟酸衍生物或其盐的制造方法
CN104327098A (zh) 一种头孢他美酸二异丙胺盐
JP3855686B2 (ja) ３，３−ジアルコキシ−２−ヒドロキシイミノ誘導体及びその製造法
WO2016158716A1 (ja) ３－ハロゲン化アルキルピラゾール誘導体の製造方法
US20060247427A1 (en) Process to obtain 6-O-methylerythromycin a (clarithromycin)_form II
JP4425373B2 (ja) ヒドロキシ−２−ハロゲノピリジン誘導体の製造方法
JP3538889B2 (ja) アルキルチオアセタミドの製造方法
JP2010083798A (ja) ω−ヒドロキシ長鎖脂肪酸誘導体の製造方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200821